Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.40 |
| ▸ | LOX | P28300 | 3/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.35 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | UTRN | P46939 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30329140 | 1.00 | RECQL (0.47) | RECQLHCRTR1HCRTR2LOXL2LOX | |
| SCHEMBL4018741 | 0.82 | RECQL (0.47) | RECQLLOXL2LOXACACB | |
| SCHEMBL18083206 | 0.82 | NOS3 (0.47) | HCRTR1HCRTR2LOXL2LOXGRM2 | |
| SCHEMBL14925194 | 0.82 | HCRTR1 (0.40) | RECQLHCRTR1HCRTR2LOXL2LOX | |
| SCHEMBL13164105 | 0.82 | LOXL2 (0.61) | HCRTR1HCRTR2LOXL2LOX | |
| SCHEMBL4536253 | 0.82 | HCRTR1 (0.40) | HCRTR1HCRTR2LOXL2LOXGRM2 | |
| SCHEMBL31191369 | 0.81 | RECQL (0.46) | RECQLLOXL2LOXACACBPLAU | |
| Hydrochloric Acid SCHEMBL25210344 | 0.81 | LOXL2 (0.59) | HCRTR1HCRTR2LOXL2LOX | |
| SCHEMBL17000198 | 0.79 | LOXL2 (0.41) | HCRTR1HCRTR2LOXL2LOXGRM2 | |
| SCHEMBL28806544 | 0.79 | HCRTR1 (0.38) | HCRTR1HCRTR2LOXL2LOXGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-08-07 | — | — | US | disclosed |
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| EP-4415706-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | Vanqua Bio, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2021069927-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-15 | — | — | WO | disclosed |
| EP-2582241-B1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2582241-B1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-04-06 | — | — | EP | disclosed |
| US-9260418-B2 | Pyranyl aryl methyl benzoquinolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20130116272-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-05-09 | — | — | US | disclosed |
| US-20130116272-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-05-09 | — | — | US | disclosed |
| EP-2582241-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2473048-A1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120157438-A1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP (US) | 2012-06-21 | — | — | US | disclosed |
| CN-102480964-A | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME | 2012-05-30 | — | — | CN | disclosed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
| WO-2011159553-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159553-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011025851-A1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | RECQL 1523/4885HCRTR1 2849/4885HCRTR2 2687/4885 |
| US-20130116272-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | RECQL 1610/4885HCRTR1 68/4885HCRTR2 99/4885 |
| US-20120157438-A1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, OPRL1 | RECQL 2402/4885HCRTR1 199/4885HCRTR2 237/4885 |
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | RECQL 2831/4885HCRTR1 176/4885HCRTR2 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.